Other mechanisms that may contribute to synergistic interaction between VEGF-pathway inhibitors and conventional cytotoxic drugs include prevention of endothelial progenitor cell mobilisation from the bone marrow induced by chemotherapy and decreased production of tumour factors conferring resistance against chemotherapy (Simakajornboon et al, 2001; Dias et al, 2002; Tran et al, 2002; Riedel et al, 2004; Shaked et al, 2008). The gene discussed is VEGFA; the disease is neoplasm.